These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 1979819

  • 1. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL, Lenz ML, Taylor AA.
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [Abstract] [Full Text] [Related]

  • 2. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [Abstract] [Full Text] [Related]

  • 3. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C, Olsson AG.
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [Abstract] [Full Text] [Related]

  • 4. Lipid results of partial ileal bypass in patients with heterozygous, type II-A hyperlipoproteinemia. Program on the Surgical Control of the Hyperlipidemias.
    Campos CT, Matts JP, Fitch LL, Speech JC, Long JM, Buchwald H.
    Surgery; 1990 Oct; 108(4):601-10; discussion 610-1. PubMed ID: 2120785
    [Abstract] [Full Text] [Related]

  • 5. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A, Daae LN, Kierulf P, Brusletto B, Holme I, Syvertsen JO.
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [Abstract] [Full Text] [Related]

  • 6. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB, Weis SE, Willis JM, Vasenius KA, McConathy WJ.
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [Abstract] [Full Text] [Related]

  • 7. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 8. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK, Bharti BB, Pandey CM, Singh U, Tewari S, Kapoor A, Garg N, Sinha N.
    Indian Heart J; 2003 Apr; 55(3):234-40. PubMed ID: 14560932
    [Abstract] [Full Text] [Related]

  • 9. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Apr; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 10. Lipoproteins and cardiovascular risk--from genetics to CHD prevention.
    Cullen P, Funke H, Schulte H, Assmann G.
    Eur Heart J; 1998 Apr; 19 Suppl C():C5-11. PubMed ID: 9597420
    [Abstract] [Full Text] [Related]

  • 11. Role of lipid and lipoprotein profiles in risk assessment and therapy.
    Ballantyne CM, Hoogeveen RC.
    Am Heart J; 2003 Aug; 146(2):227-33. PubMed ID: 12891189
    [Abstract] [Full Text] [Related]

  • 12. Search for an optimal atherogenic lipid risk profile: from the Framingham Study.
    Nam BH, Kannel WB, D'Agostino RB.
    Am J Cardiol; 2006 Feb 01; 97(3):372-5. PubMed ID: 16442398
    [Abstract] [Full Text] [Related]

  • 13. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug 01; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 14. New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III.
    Talbert RL.
    Am J Manag Care; 2002 Sep 01; 8(12 Suppl):S301-7. PubMed ID: 12240701
    [Abstract] [Full Text] [Related]

  • 15. Antihypertensive drugs and blood lipids: the Oslo study.
    Leren P, Eide I, Foss OP, Helgeland A, Hjermann I, Holme I, Kjeldsen SE, Lund-Larsen PG.
    J Cardiovasc Pharmacol; 1982 Sep 01; 4 Suppl 2():S222-4. PubMed ID: 6177960
    [Abstract] [Full Text] [Related]

  • 16. The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
    Assmann G, Schulte H, Funke H, von Eckardstein A.
    Eur Heart J; 1998 Oct 01; 19 Suppl M():M8-14. PubMed ID: 9821011
    [Abstract] [Full Text] [Related]

  • 17. [Lipids, lipoproteins, arterial accidents and oral contraceptives].
    Bakir R, Hilliquin P.
    Contracept Fertil Sex (Paris); 1986 Jan 01; 14(1):81-7. PubMed ID: 12341243
    [Abstract] [Full Text] [Related]

  • 18. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP, Pépin GM, Mahley RW.
    Am Heart J; 2003 Dec 01; 146(6):1052-9. PubMed ID: 14660998
    [Abstract] [Full Text] [Related]

  • 19. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL, Taylor AA, Nelson EB.
    Am J Med; 1989 Aug 16; 87(2A):57S-61S. PubMed ID: 2569825
    [Abstract] [Full Text] [Related]

  • 20. Metabolic changes during antihypertensive therapies.
    Krone W, Nägele H.
    J Hum Hypertens; 1989 Dec 16; 3 Suppl 2():69-73; discussion 74. PubMed ID: 2575177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.